Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) is the sixth most common cancer in the UK and represents a heterogenous group of malignancies. This article gives a brief overview of current classification of B and T cell NHL, the increased understanding of molecular and cytogenetic abnormalities associated with their pathogenesis, as well as current management principles. Although advances in immuno-chemotherapy and supportive care have resulted in better patient outcomes, many challenges remain, especially with relapsed and refractory disease. The recent introduction of novel agents in the treatment of lymphoma has resulted in some promising outcomes.